middle.news
Neurotech Advances Phase 3 Autism Trial and Safety Data for NTI164
10:14am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Neurotech Advances Phase 3 Autism Trial and Safety Data for NTI164
10:14am on Wednesday 29th of April, 2026 AEST
Key Points
First Phase 3 site activated at Monash Children’s Hospital
NTI164 shows no dose-limiting toxicities in 90-day GLP study
Clinical and mechanistic data for PANS published in Neurotherapeutics
Collaboration with University of Sydney on Rett syndrome research
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE